Anastrozole and fulvestrant compared to anastrozole as adjuvant treatment of postmenopausal patients with breast cancer - @FAME
Study identifier:D6990C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomised Phase II Study comparing anastrozole and fulvestrant to anastrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow
Medical condition
Breast Cancer
Phase
Phase 2
Healthy volunteers
No
Study drug
Fulvestrant, Anastrozole
Sex
Female
Actual Enrollment
13
Study type
Interventional
Age
N/A
Date
Study Start Date: 01 Apr 2006
Primary Completion Date: 01 Oct 2008
Study Completion Date: 01 Oct 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 1 Anastrozole monotherapy | Drug: Anastrozole 1 mg oral tablet Other Name: Arimidex Other Name: ZD1033 |
| Experimental: 2 Anastrozole + Fulvestrant | Drug: Fulvestrant intramuscular injection Other Name: Faslodex Other Name: ZD9238 Drug: Anastrozole 1 mg oral tablet Other Name: Arimidex Other Name: ZD1033 |
Contacts
Investigators
Principal Investigator
Breast Cancer Established Brands Team Medical Science Director
AstraZeneca
